In patients with intraductal carcinoma, the incidence of BRCA2 germline mutations reported in the literature is higher than for adenocarcinoma, while the data for somatic mutations are similar to the rest of patients with prostatic carcinoma [19,20]. This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.